Cargando…
Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial
This double-blind, randomized, placebo/controlled, crossover study evaluated the efficacy of Eriomin(®) in reducing hyperglycemia and improving diabetes-related biomarkers in individuals with hyperglycemia above 110 mg/dL (mean 123 ± 18 mg/dL). Subjects (n = 30), divided into two groups (Eriomin or...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700344/ https://www.ncbi.nlm.nih.gov/pubmed/35796695 http://dx.doi.org/10.1089/jmf.2021.0181 |
_version_ | 1784839289650020352 |
---|---|
author | Cesar, Thais Borges Ramos, Fernanda Maria Manzini Ribeiro, Carolina Barbosa |
author_facet | Cesar, Thais Borges Ramos, Fernanda Maria Manzini Ribeiro, Carolina Barbosa |
author_sort | Cesar, Thais Borges |
collection | PubMed |
description | This double-blind, randomized, placebo/controlled, crossover study evaluated the efficacy of Eriomin(®) in reducing hyperglycemia and improving diabetes-related biomarkers in individuals with hyperglycemia above 110 mg/dL (mean 123 ± 18 mg/dL). Subjects (n = 30), divided into two groups (Eriomin or Placebo), who received a dose of 200 mg/d of the designated supplement for 12 weeks and, after a washout period of 2 weeks, switched to the other supplement in the following 12 weeks. Assessments of biochemical, metabolic, inflammatory, blood pressure, anthropometry, and dietary parameters were performed at the beginning and end of each intervention. Treatment with 200 mg/d of Eriomin significantly decreased blood glucose (−5%), homeostasis model assessment of insulin resistance (−11%), glucagon (−13%), interleukin-6 (−14%), tumor necrosis factor alpha (−20%), and alkaline phosphatase (−13%); but increased glucagon-like peptide 1 (GLP-1) by (17%) (P ≤ .05). At the end of the placebo period, there was a 13% increase in triglycerides (P ≤ .05). Other parameters evaluated did not change with Eriomin or placebo. In conclusion, intervention with Eriomin benefited the glycemic control of prediabetic and diabetic patients, with higher blood glucose levels, by increasing GLP-1 and decreasing systemic inflammation. |
format | Online Article Text |
id | pubmed-9700344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-97003442022-11-30 Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial Cesar, Thais Borges Ramos, Fernanda Maria Manzini Ribeiro, Carolina Barbosa J Med Food Full Communications This double-blind, randomized, placebo/controlled, crossover study evaluated the efficacy of Eriomin(®) in reducing hyperglycemia and improving diabetes-related biomarkers in individuals with hyperglycemia above 110 mg/dL (mean 123 ± 18 mg/dL). Subjects (n = 30), divided into two groups (Eriomin or Placebo), who received a dose of 200 mg/d of the designated supplement for 12 weeks and, after a washout period of 2 weeks, switched to the other supplement in the following 12 weeks. Assessments of biochemical, metabolic, inflammatory, blood pressure, anthropometry, and dietary parameters were performed at the beginning and end of each intervention. Treatment with 200 mg/d of Eriomin significantly decreased blood glucose (−5%), homeostasis model assessment of insulin resistance (−11%), glucagon (−13%), interleukin-6 (−14%), tumor necrosis factor alpha (−20%), and alkaline phosphatase (−13%); but increased glucagon-like peptide 1 (GLP-1) by (17%) (P ≤ .05). At the end of the placebo period, there was a 13% increase in triglycerides (P ≤ .05). Other parameters evaluated did not change with Eriomin or placebo. In conclusion, intervention with Eriomin benefited the glycemic control of prediabetic and diabetic patients, with higher blood glucose levels, by increasing GLP-1 and decreasing systemic inflammation. Mary Ann Liebert, Inc., publishers 2022-11-01 2022-11-09 /pmc/articles/PMC9700344/ /pubmed/35796695 http://dx.doi.org/10.1089/jmf.2021.0181 Text en © Thais Borges Cesar, et al., 2022; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Full Communications Cesar, Thais Borges Ramos, Fernanda Maria Manzini Ribeiro, Carolina Barbosa Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial |
title | Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial |
title_full | Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial |
title_fullStr | Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial |
title_full_unstemmed | Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial |
title_short | Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial |
title_sort | nutraceutical eriocitrin (eriomin) reduces hyperglycemia by increasing glucagon-like peptide 1 and downregulates systemic inflammation: a crossover-randomized clinical trial |
topic | Full Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700344/ https://www.ncbi.nlm.nih.gov/pubmed/35796695 http://dx.doi.org/10.1089/jmf.2021.0181 |
work_keys_str_mv | AT cesarthaisborges nutraceuticaleriocitrineriominreduceshyperglycemiabyincreasingglucagonlikepeptide1anddownregulatessystemicinflammationacrossoverrandomizedclinicaltrial AT ramosfernandamariamanzini nutraceuticaleriocitrineriominreduceshyperglycemiabyincreasingglucagonlikepeptide1anddownregulatessystemicinflammationacrossoverrandomizedclinicaltrial AT ribeirocarolinabarbosa nutraceuticaleriocitrineriominreduceshyperglycemiabyincreasingglucagonlikepeptide1anddownregulatessystemicinflammationacrossoverrandomizedclinicaltrial |